CIDEC Antibody

What is CIDEC and why is it significant in research?

CIDEC (Cell Death Inducing DFFA Like Effector c) is a protein involved in lipid metabolism and adipocyte function. It is also known by several other names including CIDE3, FSP27, CIDE-3, FPLD5, cell death activator CIDE-3, and fat specific protein 27 . The protein has a molecular weight of approximately 26.8 kilodaltons. CIDEC is significant in research due to its critical role in lipid droplet formation, adipocyte development, and its implication in metabolic disorders including obesity, insulin resistance, and familial partial lipodystrophy type 5 (FPLD5). Understanding CIDEC function through antibody-based detection methods has provided valuable insights into adipose tissue biology and metabolic disease mechanisms.

What species reactivity is available for CIDEC antibodies?

CIDEC antibodies are available with reactivity to multiple species including human, mouse, and rat models . Based on gene homology, researchers can also find antibodies suitable for studies in canine, porcine, and non-human primate models. When selecting a CIDEC antibody for cross-species studies, it is essential to verify the specific epitope conservation across target species. Multiple suppliers offer antibodies with varying species reactivity profiles, allowing researchers to select the most appropriate antibody based on their experimental model system.

What applications are CIDEC antibodies validated for?

CIDEC antibodies have been validated for multiple experimental applications including Western Blot (WB), Enzyme-Linked Immunosorbent Assay (ELISA), Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (IHC), and Flow Cytometry (FCM) . The application versatility makes these antibodies valuable tools for comprehensive investigation of CIDEC expression, localization, and function. When designing experiments, researchers should select antibodies specifically validated for their intended application to ensure optimal results and data reliability.

How should I optimize Western blot protocols for CIDEC detection?

For optimal Western blot detection of CIDEC, researchers should implement several key protocol considerations. First, ensure proper sample preparation by using adipose tissue or adipocyte cultures with appropriate lysis buffers containing protease inhibitors. Given CIDEC's molecular weight of 26.8 kDa, use 12-15% polyacrylamide gels for optimal separation. For membrane transfer, PVDF membranes typically yield better results than nitrocellulose for this protein. Blocking should be performed with 5% non-fat milk or BSA in TBS-T. When selecting primary antibodies, those specifically validated for Western blot applications should be used at manufacturer-recommended dilutions (typically 1:500 to 1:1000) . Signal detection can be enhanced by using high-sensitivity chemiluminescent substrates or fluorescent secondary antibodies. For troubleshooting weak signals, consider longer primary antibody incubation at 4°C overnight and optimization of antibody concentration.

What are the critical considerations for immunohistochemical detection of CIDEC?

Successful immunohistochemical detection of CIDEC requires attention to several methodological details. Tissue fixation should be optimized, with 10% neutral buffered formalin typically providing good results for adipose tissue samples. Antigen retrieval is crucial, with heat-induced epitope retrieval using citrate buffer (pH 6.0) often yielding optimal staining. When selecting antibodies, those specifically validated for IHC-p (paraffin) or IHC-fr (frozen sections) should be used according to the sample preparation method . Dilution optimization is essential, with titration experiments recommended to determine ideal concentration for specific tissue types. Positive controls should include white adipose tissue samples, while negative controls should omit primary antibody. For dual immunostaining, careful selection of compatible antibody pairs from different host species is necessary to avoid cross-reactivity. Signal development systems should be selected based on required sensitivity, with tyramide signal amplification being valuable for detecting low-abundance CIDEC expression in certain contexts.

How can I validate the specificity of my CIDEC antibody?

Validating CIDEC antibody specificity requires a multi-faceted approach. Begin with positive and negative control samples - adipose tissue typically expresses high levels of CIDEC and serves as an excellent positive control, while tissues known not to express CIDEC can serve as negative controls. For definitive validation, CIDEC knockdown or knockout cells/tissues provide gold-standard negative controls. Western blot analysis should show a single band at the expected molecular weight (26.8 kDa), though post-translational modifications may result in slight variations . Pre-absorption tests using the immunizing peptide can confirm binding specificity. Cross-reactivity testing with other CIDE family members (CIDEA, CIDEB) is important to ensure selectivity within this protein family. Finally, comparing staining patterns across multiple antibodies targeting different CIDEC epitopes can provide additional confidence in specificity.

How can CIDEC antibodies be utilized in studying metabolic disease mechanisms?

CIDEC antibodies serve as powerful tools for investigating metabolic disease mechanisms through multiple advanced approaches. In obesity research, quantitative immunoblotting with CIDEC antibodies can reveal expression changes in adipose depots, correlating with lipid storage capacity and insulin sensitivity markers. For diabetes studies, dual immunofluorescence combining CIDEC antibodies with insulin signaling pathway markers (like phospho-Akt) can reveal spatial relationships between lipid droplet proteins and insulin resistance development . In lipodystrophy investigations, particularly FPLD5 which is directly linked to CIDEC mutations, antibodies recognizing specific domains can help distinguish between normal and mutant protein localization and function. Co-immunoprecipitation experiments using CIDEC antibodies can identify novel protein interaction partners in different metabolic states. For translational research, patient adipose biopsies can be analyzed by immunohistochemistry to correlate CIDEC expression patterns with clinical parameters, providing insights into potential biomarker applications.

What approaches can resolve contradictory data when studying CIDEC expression patterns?

When confronted with contradictory CIDEC expression data, researchers should implement a systematic troubleshooting approach. First, compare antibody epitopes – different antibodies targeting distinct domains of CIDEC may yield varying results due to epitope masking, conformational changes, or isoform specificity . Second, evaluate experimental conditions across studies, as CIDEC expression is highly responsive to nutritional state, temperature, and hormone levels in cellular and animal models. Third, consider post-translational modifications, as CIDEC undergoes phosphorylation and ubiquitination which may affect antibody recognition. Fourth, verify sample preparation methods, as lipid-rich tissues require specialized fixation and processing protocols for optimal antigen preservation. Fifth, implement multiple detection methodologies (Western blot, qPCR, immunostaining) to triangulate true expression levels. Finally, genetic verification using CRISPR-edited cells with epitope tags on endogenous CIDEC can provide definitive validation of expression patterns observed with commercial antibodies.

How can CIDEC antibodies be employed in studying protein-protein interactions?

CIDEC antibodies can be strategically employed to investigate protein-protein interactions through several sophisticated methodologies. Co-immunoprecipitation (Co-IP) using CIDEC antibodies can pull down intact protein complexes from adipocyte lysates, with subsequent mass spectrometry analysis identifying novel interaction partners. For studying interactions in their native cellular context, proximity ligation assays combine CIDEC antibodies with antibodies against suspected interaction partners to generate fluorescent signals only when proteins are in close proximity (<40nm) . FRET (Förster Resonance Energy Transfer) microscopy using fluorophore-conjugated CIDEC antibodies enables real-time visualization of protein interactions in living cells. For validation of direct interactions, in vitro binding assays with recombinant proteins and domain-specific CIDEC antibodies can map interaction interfaces. When investigating the functional significance of interactions, antibodies targeting specific CIDEC domains can be used to competitively disrupt protein complexes in permeabilized cell systems. These approaches collectively provide a comprehensive toolkit for dissecting the CIDEC interactome in normal and pathological states.

How do different immunodetection methods compare for CIDEC research?

Different immunodetection methods offer distinct advantages for CIDEC research depending on experimental objectives. Western blotting provides precise molecular weight verification (26.8 kDa for CIDEC) and semi-quantitative expression analysis but sacrifices spatial information . Immunohistochemistry/immunofluorescence preserves tissue architecture, allowing visualization of CIDEC's characteristic ring-like distribution around lipid droplets and correlation with histopathological features. Flow cytometry enables high-throughput quantification of CIDEC expression at the single-cell level, facilitating population analysis and cell sorting for downstream applications. ELISA offers the highest quantitative precision for measuring CIDEC protein levels in biological fluids or lysates but lacks spatial resolution. Proximity ligation assays provide superior sensitivity for detecting protein-protein interactions involving CIDEC with minimal background. Super-resolution microscopy techniques (STORM, PALM) combined with appropriate antibodies can resolve nanoscale organization of CIDEC around lipid droplets beyond conventional microscopy limits. Each method should be selected based on whether protein quantity, localization, interaction, or functional state is the primary research question.

What controls are essential when using CIDEC antibodies for immunofluorescence studies?

When conducting immunofluorescence studies with CIDEC antibodies, a comprehensive control strategy is essential for result validation. Primary controls should include positive tissue controls (adipose tissue) exhibiting the characteristic ring-like pattern of CIDEC around lipid droplets . Negative controls must include both technical controls (primary antibody omission) and biological controls (tissues or cells known not to express CIDEC). For definitive validation, CIDEC knockdown/knockout samples processed in parallel provide the gold standard negative control. Absorption controls using the immunizing peptide can confirm binding specificity. When performing co-localization studies, single-staining controls are necessary to detect any bleed-through between fluorescence channels. Isotype controls matching the primary antibody class help distinguish specific binding from Fc receptor interactions in certain cell types. For quantitative immunofluorescence, calibration controls using standardized fluorescent beads enable normalization across experimental sessions. Finally, cells transfected with tagged CIDEC constructs can serve as reference standards for antibody recognition patterns.

How should researchers interpret variability in CIDEC antibody staining patterns?

Interpreting variability in CIDEC antibody staining patterns requires consideration of both technical and biological factors. From a technical perspective, variations may result from differences in antibody clones, epitope accessibility, fixation methods, or detection systems . Antibodies targeting different domains of CIDEC may yield distinct patterns, particularly if certain regions are involved in protein-protein interactions or embedded in membranes. Biologically, CIDEC localization changes dramatically during adipocyte differentiation, shifting from diffuse cytoplasmic distribution in preadipocytes to concentrated rings around expanding lipid droplets in mature adipocytes. Nutritional status significantly impacts CIDEC expression and localization, with fasting and feeding cycles causing dynamic changes. Pathological states like insulin resistance alter CIDEC distribution patterns, potentially causing fragmentation of the typical ring structure. Species differences should also be considered, as the subcellular distribution may vary between human and rodent adipocytes. When encountering unexpected staining patterns, researchers should implement dual-labeling with lipid droplet markers (PLIN1/perilipin) and counterstaining of nuclei (DAPI) and lipids (BODIPY or Oil Red O) to provide contextual information for accurate interpretation.

What applications are available across different CIDEC antibody products?

This table summarizes the availability of CIDEC antibodies across different applications based on the analyzed search results . The data indicates that while Western blot applications have the highest number of validated antibodies, there is substantial coverage across all major immunodetection methods, providing researchers with flexibility in experimental design.

How do CIDEC antibody conjugates compare in advanced applications?

This comparative table highlights the diversity of CIDEC antibody conjugates available for advanced research applications . The selection of appropriate conjugate depends on the specific research question, detection method, and need for multiplexing or signal amplification. Unconjugated antibodies offer maximum flexibility but require additional detection steps, while directly conjugated antibodies provide streamlined workflows at the potential cost of signal strength.

What strategies can resolve weak or absent CIDEC signals in Western blot applications?

When encountering weak or absent CIDEC signals in Western blot applications, researchers should implement a systematic optimization strategy. First, ensure proper sample preparation—CIDEC is highly expressed in adipose tissue and differentiated adipocytes, so confirm appropriate cell/tissue selection . Given CIDEC's association with lipid droplets, specialized lysis buffers containing non-ionic detergents (1-2% Triton X-100) may improve extraction efficiency. Sample loading should be optimized, with 30-50μg of total protein typically sufficient for detection. For transfer optimization, use PVDF membranes rather than nitrocellulose and consider lowering methanol concentration in transfer buffer to enhance transfer efficiency of this hydrophobic protein. Primary antibody incubation can be extended to overnight at 4°C and concentration increased incrementally if signals remain weak. Signal enhancement systems including biotin-streptavidin amplification or high-sensitivity chemiluminescent substrates may be necessary for detecting low-abundance expression. If problems persist, try alternative antibodies targeting different epitopes, as protein modifications or conformational changes may mask specific regions. For degradation issues, strengthen protease inhibitor cocktails and maintain samples at 4°C throughout processing.

How can researchers optimize immunohistochemical detection of CIDEC in difficult tissue samples?

Optimizing immunohistochemical detection of CIDEC in challenging tissue samples requires addressing several critical factors. For adipose tissue, which presents particular difficulties due to high lipid content, fixation optimization is crucial—using 4% paraformaldehyde for 24-48 hours rather than standard 10% formalin may better preserve antigenicity while maintaining structure . Antigen retrieval protocols should be systematically tested, comparing heat-induced epitope retrieval using citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0), with the latter often superior for revealing masked epitopes in lipid-rich environments. For permeabilization, Triton X-100 concentration should be increased to 0.3-0.5% for adipose tissues to ensure antibody accessibility to lipid droplet-associated CIDEC. Background reduction can be achieved by extended blocking (overnight at 4°C) with serum matching the host species of the secondary antibody plus 1% BSA. Signal amplification systems including tyramide signal amplification or polymer-based detection can significantly enhance sensitivity. For frozen sections, optimal cutting temperature is critical—adipose tissue should be sectioned at -25°C to -30°C rather than standard -20°C to maintain structural integrity. When analyzing CIDEC in liver samples from steatosis models, Oil Red O counterstaining can provide contextual information about lipid droplet localization relative to CIDEC immunoreactivity.

How might new antibody technologies advance CIDEC research in metabolic disease?

Emerging antibody technologies offer promising avenues for advancing CIDEC research in metabolic disease contexts. Single-domain antibodies (nanobodies) derived from camelid species provide superior penetration into lipid-rich environments and can access epitopes unavailable to conventional antibodies, potentially revealing new aspects of CIDEC function around lipid droplets . Antibody fragments with enhanced tissue penetration could improve in vivo imaging of CIDEC distribution in adipose depots. Bispecific antibodies simultaneously targeting CIDEC and other lipid droplet proteins (like perilipins) would enable precise investigation of protein complex formation during lipid droplet fusion events characteristic of adipocyte maturation. Phospho-specific antibodies recognizing post-translationally modified CIDEC would illuminate signaling pathways regulating its activity in response to metabolic stimuli. For dynamic studies, photoswitchable antibody conjugates compatible with super-resolution microscopy could track CIDEC molecule movement during lipid droplet remodeling events. In therapeutic contexts, intrabodies (intracellularly expressed antibodies) targeting specific CIDEC domains could modulate its function in cellular models of metabolic disease, potentially identifying druggable interaction surfaces. These technological advances collectively promise to transform our understanding of CIDEC biology from static observations to dynamic, mechanistic insights with therapeutic relevance.

What emerging applications of CIDEC antibodies show promise for clinical translation?

Several emerging applications of CIDEC antibodies demonstrate significant potential for clinical translation in metabolic disease management. Immunohistochemical analysis of CIDEC expression patterns in adipose tissue biopsies could serve as a biomarker for adipocyte functionality, potentially predicting metabolic disease progression before systemic manifestations appear . Multiplex immunoassays incorporating CIDEC alongside other adipokines in blood samples might provide comprehensive metabolic health profiles for personalized intervention strategies. In pharmacological research, high-content screening platforms using CIDEC antibodies could identify compounds modulating lipid droplet dynamics and adipocyte function for therapeutic development. For precision medicine applications, antibodies specifically recognizing mutant CIDEC variants associated with familial partial lipodystrophy could enable targeted diagnostic approaches in at-risk populations. Liquid biopsy techniques detecting circulating adipocyte fragments with CIDEC immunoreactivity might serve as minimally invasive indicators of adipose tissue dysfunction. In obesity management, longitudinal monitoring of CIDEC expression patterns before and after interventions (dietary, surgical, or pharmacological) could provide molecular-level evidence of treatment efficacy beyond conventional metabolic parameters. These translational applications highlight how fundamental research tools can bridge the gap between basic CIDEC biology and clinical relevance in addressing the global metabolic disease epidemic.